Major shareholder announcement filed by Genmab (GNMSF) in Form 6-K

Rhea-AI Filing Summary

Genmab A/S has furnished a Form 6-K for September 2025 that attaches two exhibits related to a major shareholder. The exhibits are a company announcement dated September 23, 2025 and a standard notification of major holdings. The filing is incorporated by reference into Genmab’s existing Form S-8 registration statements.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF SEPTEMBER 2025

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated September 23, 2025: Major Shareholder Announcement
99.2			Standard form for notification of major holdings

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: SEPTEMBER 23, 2025

FAQ

What does Genmab A/S (GNMSF) report in this September 2025 Form 6-K?

Genmab A/S reports a Form 6-K furnishing information on a major shareholder. It includes a company announcement dated September 23, 2025 and a standard notification of major holdings as exhibits related to that ownership disclosure.

Which exhibits are included in the Genmab (GNMSF) September 2025 Form 6-K?

The Form 6-K includes two exhibits: a company announcement dated September 23, 2025 about a major shareholder and a standard form for notification of major holdings. Together, they provide formal disclosure of significant share ownership.

How is this Genmab A/S (GNMSF) Form 6-K used in its registration statements?

The Form 6-K is incorporated by reference into Genmab A/S’s Form S-8 registration statements. This means the major shareholder announcement and related notification become part of several existing equity compensation registration filings.

Which Genmab (GNMSF) Form S-8 registrations are affected by this Form 6-K?

The Form 6-K is incorporated into Genmab’s Form S-8 registration statements with file numbers 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876. These registrations typically cover employee equity compensation plans.

Who signed the September 2025 Genmab A/S (GNMSF) Form 6-K?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano. He is identified as the company’s Executive Vice President and Chief Financial Officer, acting as the authorized signatory for this filing.